SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Sleepman who wrote (26546)11/16/1998 7:27:00 PM
From: Machaon  Respond to of 32384
 
Thanks for your evaluation of today's FDA action, Dan.

<< A local therapy would not be expected to be a first line therapy >>

Good point.

Perhaps the negative market reaction was more reflective of the earnings report than the FDA panel approval? I was a little disappointed in their revenues, but I really didn't know what to expect, and I really didn't care too much about the quarterly financials at this time, unless they were really out of line.

Regards, Bob



To: Sleepman who wrote (26546)11/16/1998 10:04:00 PM
From: Henry Niman  Respond to of 32384
 
The BUY recs today emphasized the fact that Panretin was the first of several drugs and the approval rec was major milestone for LGND. I think that today's selling was due to selling on the news, losses a nickel more than consensus, and misunderstanding of the market for the drug.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News